Investor Relations **Web:** http://ir.tevapharm.com
T: +1 (267) 468-4743 **Email:** TevaInvestorRelations@tevapharm.com

Q4 2021 Debt Analysis

Debt Maturities ($ billion)



$20.9B Net Debt
$23.0B Gross Debt

Moody's Ba2/Stable
S&P BB-/Stable

Duration 6.4
WAC 4.00%

Net Debt/EBITDA Ratio



	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21
Leverage	70%	69%	69%	67%	67%
Net Debt ($ Bn)	23.7	23.2	22.7	21.7	20.9
ST/Total Debt	12%	11%	14%	11%	6%
Gross Debt/ EBITDA	5.3x	5.3x	5.2x	4.9x	4.7x



Debt Composition